Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Irrelevant at this cvm stage but will simply future trials for other types of cancer.
Do you have a link to the source?
What do you foresee, sushi, will you buy CVM eventually? What would be the trigger for that?
If tlss manages to pull that off... So far, the management has been ambitious, very disciplined and performing really well.
Why?
To your last post, the p3 protocol should be public and therefore the fact that chemo didn't have to wait 3 weeks for surgery. If that is the case, I see no harm in responding to private queries regarding publicly available information.
Odd though that Geert did not use the opportunity to communicate this fact to the wider audience. That should strengthen the case of Multikine further.
When do you reckon we may expect 5 cents?
Ant reason for that happens besides your opinion? No offense.
The blog entry says otherwise, with facts: https://www.cvmresearch.com/p/cel-sci-cvm-fdas-recent-subgroup?utm_source=%2Fprofile%2F41376696-cvm-research&utm_medium=reader2
What are your thoughts, Sushi?
I suspect the following. Cvm can identify individuals that would benefit from Multikine across both treatment groups. Cvm also knowns which individuals were improving prior receiving chemo and would have faired well if not for the chemo.
Given the above, cvm is either:
1. (Optimistic) applying for a license to treat everyone that can be identified as receptive to treatment potentially even replacing chemo, but that involves a difficult discussion with fda that takes time.
2. (Realistic) applying to treat only the subgroup w/o chemo but the method to identify the target group of patients in advance is arguable.
:D are you expecting exciting news, Sushi?
Thank you for the link
So far none of my investments have unfolded as anticipated, CVM being one of them.
I expect some twists with NWBO's results. For example the original primary endpoint may fail, but the new one would pass - this will give pessimists an opportunity to bring down the share price albeit temporarily followed by an eventual surge.
Another example would see both primary endpoints fail but as with CVM a meaningful subgroup with tremendous success would be identified. Again, that would drop the sp temporarily.
I do hope for the most optimistic scenario of nailing both old and new primary endpoints but simply being cautious now in order not to get disappointed too much.
Ultimately, I am absolutely certain that DCVax will reach the market, the question is how quickly and how big will the market be.
Is everyone expecting stellar and unambiguous results? I sure hope for the sake of patients and investors, but experience with $CVM says certainly is not that certain.
Not ideal as the information can be "spinned" the way presenters would like or claimed as such. A journal publication would be a more solid statement, much more difficult to object.
No, I can't be angry. Bad trades of mine are of my fault - I'm making the final decision. I'm envious in a good sense.
Does it mean... Asco accepts abstracts of any quality?
Only if you shared your actions on a timely manner and not post factum :) Your track record is something to be envy of.
Yes yes, that's what I meant. I would have thought you've sold this batch the very same day when it was up a tad bit!
I thought you'd have sold your $3s at the top the very same day you bought them
Anticipating $2s before ASCO. Not an oracle, just a guess.
I'm sure Geert did not have any bad intentions, rather impatience due to excitement and anticipation of good results. Who wouldn't want to share those asap?
Imho Geert makes the same mistake of jumping the gun. He should wait for definite facts before making announcements. May as well be participants' misinterpretation.
I anticipate disappointment tomorrow.
Good catch. We don't know the feedback, but what can Geert announce tomorrow if the submission is not final?
In theory, can you be held liable for spreading such rumours?
Thank you
Aren't companies required to publish the results no later than one year from study completion?
Can't find the protocol but would be interesting to read about it more myself.
Thanks, now I understand what you were referring to
Zeppo, could you please point me to the article?
I'm fairly confident that the subgroup question is not going to be an issue as outlined at https://www.cvmresearch.com/p/cel-sci-cvm-fdas-recent-subgroup and https://irdirect.net/prviewer/release_only/id/4766430
That's very normal, even fairly fast, for an academic publication in a journal.
A very informative article. Looking forward to learning more about: "The proposed pre-selection methodology to determine which patients will receive radiation after surgery is appropriate."
Thanks for elaborating!
What's the patent situation with Multikine? A well known chronic short on StockTwits has shared that Multikine patent in the US is going to run out in two years https://stocktwits.com/ThaDreadPirate/message/353803229
According to the source https://patents.google.com/patent/EP1773368B1/en the patent is active in the EU but not in the US. Perhaps CelSci can extend the patent?
I understood the sp increase was in anticipation of the early halt.
Good to know and will come in handy once we learn more details. Difficult to draw any conclusions without more information though.
I do not understand how the company can release such an incomplete statement to the public. It's incompetent and irresponsible to say the least.
Was chemo prescribed before the treatment has begun? That is my understanding.
Do you have the info source?
Why on earth would you do that? If the results are good then great, if they're bad you're toast anyway.
Now this incomplete set of information is causing toxicity in the community and unnecessary frustration regardless of what's the end result.
The optimistic side of me wants to think this is down to poor PR handling skills.